Page last updated: 2024-12-11

bms184476

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6918461
CHEMBL ID4297267
SCHEMBL ID12168429
MeSH IDM0387905

Synonyms (21)

Synonym
bms-184476
7-methylthiomethylpaclitaxel
SCHEMBL12168429
paclitaxel, 7-((methylthio)methyl)-
7-((methylthio)methyl)paclitaxel
bms184476
3811w2nbz8 ,
7-o-((methylthio)methyl)paclitaxel
benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-6,12b-bis(acetyloxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4-((methylthio)methoxy)-5-oxo-7,11-
bms 184476
160237-25-2
7-methylthiomethyl-paclitaxel
unii-3811w2nbz8
7-methylthiomethylpaclitaxel [who-dd]
paclitaxel-7-methylthiomethyl ether
DB12633
DTXSID30873340
7-[(methylthio)methyl]paclitaxel
[(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4,12-diacetyloxy-15-[(2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-9-(methylsulfanylmethoxy)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Q27256717
CHEMBL4297267

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Mean +/- SD values for clearance, volume of distribution at steady-state, and terminal half-life were 220 +/- 89 mL/min/m2, 402 +/- 231 L/m2, and 40."( Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Aylesworth, C; Britten, CD; Felton, S; Ferrante, KJ; Gupta, E; Hammond, LA; Hidalgo, M; Molpus, K; Patnaik, A; Rowinsky, EK; Schwartz, G; Skillings, J; Smith, L; Sonnichsen, DS; Stephenson, J; Tortora, A; Weiss, G, 2001
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
"The aim of this study was to define the maximum tolerated dose (MTD) and the pharmacological profile of the paclitaxel analogue BMS-184476 given once every 3 weeks, or on days 1 and 8 every 3 weeks (d1&8), in combination with a fixed dose of 50 mg/m(2) of Doxorubicin (Doxo) administered on day 1 of a 21-day cycle."( Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
Capri, G; Colombini, S; Gianni, L; Lladò, A; Locatelli, A; Marsoni, S; Minotti, G; Peccatori, F; Perotti, A; Salvatorelli, E; Sessa, C; Viganò, L; Voi, M, 2004
)
0.32
"The aim of the study was to determine the maximum-tolerated dose and dose-limiting toxicities for BMS-184476, in combination with carboplatin, in patients with advanced solid tumours and to describe any preliminary antitumour activity associated with this regimen."( Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days.
Bilenker, JH; Cohen, MB; Gallagher, ML; O'Dwyer, PJ; Stevenson, JP; Vaughn, D, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Neutropenia at the higher dose levels frequently prevented administration of the day 15 dose, and a modified schedule at MTD dosing on days 1 and 8 every 21 days was evaluated and found more feasible for Phase II studies."( Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Calvert, H; Calvert, P; Gallant, G; Ghielmini, M; Gupta, E; Plummer, R; Renard, J; Sessa, C; Voi, M, 2002
)
0.31
" Dosing of BMS-184476 for 2 consecutive weeks allowed the administration of larger doses of the taxane with a promising antitumour activity in patients with untreated or minimally pretreated breast cancer."( Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
Capri, G; Colombini, S; Gianni, L; Lladò, A; Locatelli, A; Marsoni, S; Minotti, G; Peccatori, F; Perotti, A; Salvatorelli, E; Sessa, C; Viganò, L; Voi, M, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (38.46%)5.53%
Reviews4 (30.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (30.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]